Posted on 1/22/19
CVS Health Named One of "World's Most Admired Companies" by FORTUNE Magazine for Fifth Consecutive Year
CVS Health (NYSE: CVS), the nation's premier health innovation company, today was recognized by FORTUNE magazine as one of the World's Most Admired Companies for the . . .
Posted on 1/22/19
Gamida Cell and Be The Match BioTherapies Announce Strategic Collaboration
BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies, a subsidiary of the National Marrow . . .
Posted on 1/22/19
Bristol-Myers/Celgene: The Spread Is Your Friend
SummaryThere is a pending 16 percent spread between the current price of Celgene and the take-out price.Investors are concerned about the viability of the deal.Celgene fits . . .
Posted on 1/22/19
Better Buy: Biogen vs. Gilead Sciences
Juggernauts. That's not a word most of us use very often. But it's a pretty good description of Biogen (NASDAQ:BIIB) in multiple sclerosis (MS). It's also . . .
Posted on 1/22/19
Is Cognex a Buy?
Machine vision specialist Cognex (NASDAQ:CGNX) is a much-admired growth company with significant exposure to many long-term growth trends -- the increasing use of automation and robotics . . .
Posted on 1/22/19
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity . . .
Posted on 1/18/19
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene
BOSTON--(BUSINESS WIRE)--Kyn Therapeutics, a clinical-stage biotechnology company advancing research into new immunometabolic therapies for treating cancer, today announced it has entered into a global strategic collaboration . . .
Posted on 1/18/19
Obsidian Therapeutics Announces Strategic Collaboration with Celgene
Companies enter into multi-year strategic collaboration with Celgene receiving exclusive options to license cell therapies that utilize Obsidian’s Destabilizing Domain technology to modulate IL12 and CD40L . . .
Posted on 1/18/19
Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018
What happenedBiopharma heavyweight Bristol-Myers Squibb (NYSE:BMY) saw its shares sink by a staggering 15.2% in 2018, according to data from S&P Global Market Intelligence. What caused . . .
Posted on 1/18/19
Aquinnah Pharmaceuticals Receives $750,000 Grant from the Alzheimer's Association and Tau Consortium
Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, announced today that it has been awarded $750,000 from the Tau . . .
Posted on 1/17/19
Boston Children’s Hospital and Medumo Announce Strategic Collaboration
BOSTON--(BUSINESS WIRE)--Boston Children’s Hospital (BCH), the #1 ranked pediatric hospital based on US News and World Report, and Medumo, a leading patient navigation platform, are excited . . .
Posted on 1/16/19
Acceleron Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare . . .
Posted on 1/16/19
Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It
SummaryThe Bristol-Myers Squibb acquisition undervalues Celgene.Bristol-Myers would also be undervalued post-deal at current prices.I am inclined to keep the BMY stock I receive.Bristol-Myers Squibb (BMY) is . . .
Posted on 1/15/19
CVS Health Announces $100 Million Community Commitment Following Acquisition Of Aetna
Following its completed acquisition of Aetna, CVS Health (NYSE: CVS) today announced a $100 million commitment to making community health and wellness central to the newly . . .
Posted on 1/15/19
Alopexx Vaccine Announces Licensing Agreement with Merck Animal Health
Alopexx Vaccine, LLC announced today that it has entered into an exclusive global license agreement with Merck Animal Health to develop and commercialize its poly-N-acetyl glucosamine . . .
Posted on 1/15/19
Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, . . .
Posted on 1/15/19
Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its . . .
Posted on 1/15/19
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its . . .
Posted on 1/15/19
RogCon and Prometheus Research Enter into Partnership
RogCon Biosciences, Inc., (RogCon), a biotechnology company leading the discovery and development of novel treatments for patients suffering from SCN2A (Nav1.2) mutations, has partnered with Prometheus . . .
Posted on 1/14/19
Healthworks Fitness Sponsors the Boston’s Women’s March and Opens Club to Recharge
Healthworks Fitness, Boston’s premier fitness clubs for women, will be marching in the Boston Women’s March on January 19th, and will open doors to participants to . . .
Posted on 1/14/19
HMR Weight Management Partners with Providence St. Joseph Health
BOSTON--(BUSINESS WIRE)--With obesity rates for American adults now at an all-time high of nearly 40%, Providence St. Joseph Health, one of the nation’s top healthcare systems, . . .
Posted on 1/14/19
Better Buy: Baker Hughes vs. Core Laboratories
It has been challenging to grow your wealth investing in oil stocks over the past few years. Even though Baker Hughes, a GE Company (NYSE:BHGE) and . . .
Posted on 1/14/19
Rhythm Pharma: Investible Based On Upcoming Trial Data
SummaryRYTM has four phase 3 trials ongoing in related genetic obesity diseases.These have each seen positive proof of concept data.The company has decent cash runway and . . .
Posted on 1/11/19
Charlotte Radiology Chooses Sectra as Its Breast Imaging Vendor
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will install its enterprise breast imaging solution throughout the fifteen North Carolina-based breast centers of . . .
Posted on 1/9/19
WeHealth by Servier and PathMaker Neurosystems Form Partnership
PARIS & BOSTON--(BUSINESS WIRE)--WeHealth by Servier, the e-health department of Servier Group, and PathMaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company, announced today the closing of . . .

